Articles by Alexander
Latest articles from the Industry Radar column
Industry Radar
The $787M Bet: How Earendil Labs' AI Biologics Deal Signals a New Pharma Investment Era
Industry Radar
Beyond the $2B Deal: How Novartis' Acquisition of Inavolisib Signals a Strategic Shift in Precision Oncology
Industry Radar
Beyond Genetics: How Rhythm Pharma's FDA Win Redefines the Obesity Market and Brain-Body Pathways
Industry Radar
Beyond the Dose: How Novo Nordisk's Priority Voucher Strategy Reveals Pharma's New Playbook
Industry Radar
Beyond the Mutation: How Pfizer's Talzenna Data Redefines Prostate Cancer Treatment Economics
Industry Radar
Beyond the 20% Surge: How Apogee's Infrequent-Dosing Eczema Drug Could Reshape the Biopharma Business Model
Industry Radar
Beyond the Headline: AstraZeneca's Shanghai Cell Therapy Bet and China's Biotech Power Play
Industry Radar
FDA's Divergent Decisions: How Clinical Trial Data Quality is Reshaping Biotech Investment
Industry Radar
Beyond the $69M: How Excalipoint's T-Cell Engagers Signal China's Strategic Shift in Biotech
A comprehensive analysis of merger and acquisition trends, licensing deals, and strategic collaborations shaping the biotech landscape in the fourth quarter of 2024.